Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma 128Leukemia, Lymphocytic, Chronic, B-Cell 96Precursor Cell Lymphoblastic Leukemia-Lymphoma 90Lymphoma, Non-Hodgkin 83Lymphoma, Follicular 76Lymphoma, Large B-Cell, Diffuse 71Leukemia 60Lymphoma, Mantle-Cell 51Burkitt Lymphoma 48Hodgkin Disease 44Leukemia, Myeloid, Acute 42Lymphoma, B-Cell, Marginal Zone 41Lymphoma, B-Cell 40Recurrence 38Lymphoma, T-Cell, Cutaneous 27Mycosis Fungoides 26Myelodysplastic Syndromes 25Waldenstrom Macroglobulinemia 24Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 24Multiple Myeloma 21Lymphoma, Large-Cell, Immunoblastic 21Lymphoma, Large-Cell, Anaplastic 21Sezary Syndrome 19Neoplasms 19Hematologic Neoplasms 18Myeloproliferative Disorders 17Lymphoma, Extranodal NK-T-Cell 16Leukemia, Myelomonocytic, Chronic 14Leukemia, Myelogenous, Chronic, BCR-ABL Positive 14Leukemia, Biphenotypic, Acute 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × EBV Lymphomas × Lymphoid × Clear all
NCT03988582 2020-06-11

Safety and Effectiveness of EBV-specific Cytotoxic T Cells for the Treatment for EBV Lymphomas or Other EBV-associated Malignancies

Memorial Sloan Kettering Cancer Center

Phase 2 Withdrawn
Lymphoid

EBV Lymphomas

Data powered by HemOnc (CC BY 4.0) Colophon âš¡